NCT01218867 (Results were tabulated on the website): 1/23 PR (metastatic melanoma and renal Ca). As DC101 mAb did not recognize human VEGF-R2 (53), the Bevacizumab or Ranibizumab, or mAb from (53) (KD from 0.49-1.1nM) are likely used. Here, KDR is linked to metastatic melanoma.